Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. Among authors: janu a. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.
The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients.
Noronha V, Joshi A, Gokarn A, Sharma V, Patil V, Janu A, Purandare N, Chougule A, Jambhekar N, Prabhash K. Noronha V, et al. Among authors: janu a. Chemother Res Pract. 2014;2014:856156. doi: 10.1155/2014/856156. Epub 2014 Dec 7. Chemother Res Pract. 2014. PMID: 25548673 Free PMC article.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil VM, et al. Among authors: janu a. ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017. ESMO Open. 2017. PMID: 28761735 Free PMC article.
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.
Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S, Goud S, Karpe A, Ramaswamy A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Noronha V, et al. Among authors: janu a. Ecancermedicalscience. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29104613 Free PMC article.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: janu a. Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23. Chemother Res Pract. 2017. PMID: 29201462 Free PMC article.
84 results